Welcome to our dedicated page for BELLEROPHON THERPETCS news (Ticker: BLPH), a resource for investors and traders seeking the latest updates and insights on BELLEROPHON THERPETCS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BELLEROPHON THERPETCS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BELLEROPHON THERPETCS's position in the market.
Bellerophon Therapeutics (Nasdaq: BLPH) provided a clinical update and financial results for Q2 2022. The company is progressing its late-stage INOpulse® therapy for fibrotic interstitial lung disease (fILD) and pulmonary hypertension associated with sarcoidosis (PH-Sarc).
Enrollment is ongoing in the Phase 3 REBUILD study, targeting 300 patients. Positive results from earlier trials showed a 20% improvement in moderate to vigorous physical activity. However, Bellerophon reported a net loss of $4.1 million for Q2 2022, with R&D expenses rising to $4.5 million due to ongoing trials.
Bellerophon Therapeutics (Nasdaq: BLPH) announced a poster presentation at the ATS 2022 International Conference, scheduled for May 17, 2022. The session, titled "It's not just about IPF," will feature research on a Phase 2 Trial of INOpulse in patients with Sarcoidosis Associated Pulmonary Hypertension requiring supplemental oxygen. The presentation will be made by Dr. Robert Baughman from the University of Cincinnati at 2:15 PM Pacific Time in the Moscone Center, San Francisco.
The ePoster will be available on the conference's viewing site.
Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) provided an update on its clinical programs and reported financial results for Q1 2022. The company is advancing the INOpulse® therapy for fibrotic interstitial lung disease (fILD) and pulmonary hypertension related to sarcoidosis (PH-Sarc). Enrollment continues in the Phase 3 REBUILD study targeting 300 patients. Financially, Bellerophon reported a net loss of $5.6 million for Q1 2022, slightly up from $5.5 million in Q1 2021, with $20 million in cash. R&D expenses rose to $4.4 million due to ongoing trials.
Bellerophon Therapeutics (BLPH) announced a clinical update and 2021 financial results, focusing on INOpulse® therapy for fibrotic interstitial lung disease (fILD) and pulmonary hypertension associated with sarcoidosis (PH-Sarc). The company reported a net loss of $17.8 million, improving from $24.7 million in 2020. Research and development expenses decreased to $13 million, attributed to discontinuing a COVID-19 trial. As of December 31, 2021, cash and equivalents were $24.7 million. Bellerophon is progressing the Phase 3 REBUILD study and evaluating a follow-up Phase 2b study for PH-Sarc.
Bellerophon Therapeutics (Nasdaq: BLPH) announced that Dr. Naseem Amin, Chairman of the Board, will present a corporate overview at the H.C. Wainwright BioConnect 2022 Conference, taking place virtually from January 10-13, 2022. The presentation will be available on-demand starting January 10 at 7:00 AM Eastern Time on the Company’s website. Bellerophon focuses on developing innovative therapies for cardiopulmonary diseases, including products under its proprietary INOpulse® program, a nitric oxide delivery system.
Bellerophon Therapeutics announced positive results from its Phase 2 dose escalation study (PULSE-PHPF-002) of INOpulse for treating pulmonary hypertension associated with sarcoidosis. The trial demonstrated that all eight subjects experienced a clinically meaningful reduction in pulmonary vascular resistance (PVR), with a median drop of 20% at the iNO45 dose and 29% at iNO125. Importantly, no treatment-emergent adverse events occurred. Bellerophon plans to advance into a multi-dose Phase 2b trial to further evaluate the efficacy of INOpulse in this indication.
Bellerophon Therapeutics (Nasdaq: BLPH) announced its third-quarter results, highlighting progress in its clinical programs, particularly for INOpulse® in fibrotic interstitial lung disease (fILD) and pulmonary hypertension-sarcoidosis (PH-Sarc).
The Company reported a net loss of $4.6 million for Q3 2021, an improvement from $7.9 million in Q3 2020. Operating loss decreased from $8.3 million to $4.8 million during the same period. Cash reserves stood at $28.7 million, a decline from $47.6 million at the end of 2020, but sufficient for ongoing developments.
Bellerophon Therapeutics (Nasdaq: BLPH) announced that CEO Fabian Tenenbaum will provide a corporate overview at the H.C. Wainwright 23rd Annual Global Investment Conference, taking place from September 13-15, 2021. The presentation will be available on-demand starting at 7:00 AM ET on September 13, accessible via the Investors section of the company's website.
Bellerophon focuses on innovative therapies for cardiopulmonary diseases and is developing multiple candidates under the INOpulse® program, a proprietary nitric oxide delivery system.
Bellerophon Therapeutics (Nasdaq: BLPH) reported a net loss of $3.4 million for Q2 2021, improving from $3.8 million in Q2 2020. The Company continues its pivotal Phase 3 REBUILD study for inhaled nitric oxide therapy in fibrotic interstitial lung disease, aiming to enroll 300 patients. Positive results from earlier studies support the treatment's efficacy. Research and development expenses increased to $6.8 million for the first half of 2021. The Company has $34.3 million in cash available for ongoing clinical programs.
Bellerophon Therapeutics (Nasdaq: BLPH) announces CEO Fabian Tenenbaum will present a corporate overview at the Jefferies Virtual Healthcare Conference from June 1-4, 2021. The presentation is scheduled for June 3, 2021, at 3:00 PM Eastern Time. Bellerophon focuses on innovative treatments for cardiopulmonary diseases, currently developing multiple candidates under its proprietary INOpulse® program. A live audio webcast and replay will be available on the Company’s website, providing investors with real-time access to this key event.
FAQ
What is the current stock price of BELLEROPHON THERPETCS (BLPH)?
What is the market cap of BELLEROPHON THERPETCS (BLPH)?
